-1 C°
Traffic jam:   7

AstraZeneca COVID-19 vaccine showed 70% efficiency

23 November 2020
2 min.
AstraZeneca COVID-19 vaccine showed 70% efficiency

The fight against covid

The British company's vaccine had an average efficiency of 70%, but one of the methods of administration showed a 90% efficiency.

AZD 1222 vaccine against coronavirus infection COVID-19, which is being developed in the UK, showed high efficiency during the tests, says the pharmaceutical company AstraZeneca. The company explained that during the tests two variants of the vaccine were tested demonstrated different efficiency.

In the first case, AZD 1222 administered to more than 2,700 people in half a dose first and a month later in full. This method of vaccination showed 90% efficacy, while the full-dose option with a montly difference of almost 9,000 test subjects was given only 62%.

The company stated that the average efficiency of the vaccine, taking into account the data from both tests, was 70 percent.

According to Professor Andrew Pollard, who led the vaccine trials in Oxford, the test results confirmed that AZD1222 can save many lives.

A. Pollard also said: "With one of the options, the vaccine can be effective by about 90%, and with the same vaccine volume, more people can be vaccinated".

AstraZeneca noted that a total of 131 cases of infection of participants in the COVID-19 trials were identified. At the same time, none of those who were ill had a serious illness and none of them needed to be hospitalised. The independent Data Safety Review Board confirmed, however, that the immunity required from protection against COVID-19 is produced 14 days after the second dose of vaccine and that no serious side effects were detected during the tests.

In November, other developers also reported on the high effectiveness of their version of the COVID-19 vaccine. For example, American Moderna estimated the effectiveness of its product at 94.5%, and Pfizer and BioNTech at 95%.

Persons1 and Companies5 in the news

Professor of paediatric infection and immunity at the University of Oxford
1 place
2 place
3 place
4 place
5 place


Rating companies
40 Mention
38 Mention
35 Mention
32 Mention
31 Mention
White House
30 Mention
Dow Jones
29 Mention


News from GlobalNY.biz is the freshest and most relevant information about high-profile events in the region. The task of the resource's news feed is to convey to readers with maximum accuracy and objectivity information about important events in business, politics, economy, healthcare, culture and other spheres of life in New York.
GlobalNY.biz news is a coverage of economic processes taking place in New York, the latest news of public life, incidents and an overview of political events. New York news is information about the activities of small and medium-sized businesses, the work of housing and communal services and utilities, the implementation of significant projects.
The site's journalists describe not only the life of the region, but also talk about the current state of the US economy. Everything you need to know about innovations in the field of industry and agriculture, economy and power is collected in the "News" section at GlobalNY.biz.
New York news quickly informs the reader, shows the real picture and opens up hot topics. Communication with government structures and business enables us to provide our readers with reliable, information-rich material. The main page of the portal contains the key news of New York!
Alena Potapova

Development Director